
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc is positioned for growth as the increasing acceptance of cell and gene therapies is anticipated to lead to a steady rise in both commercial revenue and clinical trial activity. Additionally, the company has seen a consistent increase in gene therapy programs across various stages, particularly in oncology and rare diseases, indicating a burgeoning pipeline of approved therapies. This positive market trend, combined with CryoPort's integral role in the life sciences supply chain across multiple global regions, supports a favorable outlook for its financial performance.
Bears say
CryoPort Inc. is experiencing a negative outlook primarily due to a continuous decline in start-up funding within the life sciences sector, particularly affecting Series A and seed funding, suggesting a tighter capital environment for companies in this space. Additionally, APCA is facing a notable slowdown in demand for MVE freezers, indicating challenges in product sales and potential revenue decline year-over-year. This combination of reduced funding and weaker demand highlights significant headwinds that could adversely impact CryoPort's financial performance moving forward.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares